Tags

Type your tag names separated by a space and hit enter

[Treatment of non-alcoholic fatty liver disease].
Ned Tijdschr Geneeskd 2011; 155:A3181NT

Abstract

Non-alcoholic fatty liver disease (NAFLD) comprises benign steatosis and steatohepatitis (NASH) and may lead to liver fibrosis, cirrhosis and hepatocellular carcinoma. Its prevalence is estimated to be 20% in the general population and 50-100% in patients with overweight and obesity. In about 15-30% of patients steatosis evolves to NASH which can only be diagnosed by means of a liver biopsy. NAFLD may be described as the hepatic component of the metabolic syndrome and is a consequence of the Western lifestyle. The pathogenesis is multifactorial; oxidative stress plays a crucial role in maintaining inflammation and progressive fibrosis. Lifestyle modification with weight loss and increased physical activity is the cornerstone of the treatment, which should take place in a multidisciplinary setting. To date, no specific registered drug for NAFLD treatment is available. Supportive drug therapy is mainly focused on aspects of the metabolic syndrome and chronic inflammation.

Authors+Show Affiliations

Maastricht Universitair Medisch Centrum, afd. Interne geneeskunde, Divisie maag-, darm-, leverziekten, Maastricht, the Netherlands. gh.koek@mumc.nl

Pub Type(s)

English Abstract
Journal Article
Review

Language

dut

PubMed ID

21649947

Citation

Koek, Ger H.. "[Treatment of Non-alcoholic Fatty Liver Disease]." Nederlands Tijdschrift Voor Geneeskunde, vol. 155, 2011, pp. A3181.
Koek GH. [Treatment of non-alcoholic fatty liver disease]. Ned Tijdschr Geneeskd. 2011;155:A3181.
Koek, G. H. (2011). [Treatment of non-alcoholic fatty liver disease]. Nederlands Tijdschrift Voor Geneeskunde, 155, pp. A3181.
Koek GH. [Treatment of Non-alcoholic Fatty Liver Disease]. Ned Tijdschr Geneeskd. 2011;155:A3181. PubMed PMID: 21649947.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of non-alcoholic fatty liver disease]. A1 - Koek,Ger H, PY - 2011/6/9/entrez PY - 2011/6/9/pubmed PY - 2011/10/6/medline SP - A3181 EP - A3181 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 155 N2 - Non-alcoholic fatty liver disease (NAFLD) comprises benign steatosis and steatohepatitis (NASH) and may lead to liver fibrosis, cirrhosis and hepatocellular carcinoma. Its prevalence is estimated to be 20% in the general population and 50-100% in patients with overweight and obesity. In about 15-30% of patients steatosis evolves to NASH which can only be diagnosed by means of a liver biopsy. NAFLD may be described as the hepatic component of the metabolic syndrome and is a consequence of the Western lifestyle. The pathogenesis is multifactorial; oxidative stress plays a crucial role in maintaining inflammation and progressive fibrosis. Lifestyle modification with weight loss and increased physical activity is the cornerstone of the treatment, which should take place in a multidisciplinary setting. To date, no specific registered drug for NAFLD treatment is available. Supportive drug therapy is mainly focused on aspects of the metabolic syndrome and chronic inflammation. SN - 1876-8784 UR - https://www.unboundmedicine.com/medline/citation/21649947/[Treatment_of_non_alcoholic_fatty_liver_disease]_ L2 - http://www.ntvg.nl/A3181 DB - PRIME DP - Unbound Medicine ER -